Abstract
DC Bead™ is a sulfonate-modified, PVA-based microspherical embolisation agent approved for the treatment of hypervascular tumours and arterio-venous malformations. The beads have previously been shown to actively sequester oppositely charged drugs, such as doxorubicin hydrochloride (dox) by an ion-exchange mechanism. In order to characterise the release kinetics and predict the in vivo behaviour of drug eluting beads (DEB), two elution methods were utilised. The first, an application of the USP dissolution method Type II - Apparatus, enables study of the complete elution of loaded DC Bead in less than 4 h, allowing relatively rapid comparison to be made between different products and formulations. Release data obtained using this method were fitted to first order kinetics (R 2 > 0.998) and the elution constants shown to increase with the total surface area of the beads exposed to the elution medium. Diffusion coefficients were calculated adopting the Fickian diffusion model, which predicted slow elution rates under physiological conditions. The second method involved the use of a T-Apparatus where the drug experiences an element of diffusion through a static environment. This method was developed to resemble the in vivo situation in embolisation procedures more closely. Slow release of dox from DC Bead with half-lives over 1,500 h were predicted for all size ranges using a slow release model. A strong linear relationship was found between the release data from T-Apparatus and pharmacokinetic data obtained from patients treated with DC Bead loaded with dox in transarterial chemoembolisation (TACE) procedures. These data indicated a Level A in vitro–in vivo correlation (IVIVC) for the first 24 h post embolisation. Both systems developed were automated and good reproducibility was obtained for all samples, demonstrating the usefulness of these elution techniques for product development and comparative testing.
Similar content being viewed by others
References
A. L. LEWIS, M. V. GONZALEZ, B. HALL, et al., JVIR 17(2) (2006) 335
A. L. LEWIS, M. V. GONZALEZ, S. W. LEPPARD, et al., J. Mater. Sci. Mater. Med. doi: 10.1007/s10856-007-3068-8
B. SPERKER, T. E. MURDTER, M. SCHICK, et al., J. Pharmacol. Exp. Ther. 281(2) (1997) 914
W. J. JUSKO, J. Pharm. Sci. 60 (1971) 892
M. J. BOYER and I. F. TANNOCK, in “Cellular and Molecular Basis of Chemotherapy. The Basic Science of Oncology” (Toronto, MacGraw-Hill Health Professions Division, 1998) p. 350
US Pharmacopeia 28, (2005)
R. Y. CHEUNG, R. KUBA, A. M. RAUTH and X. Y. WU, J. Control Release 94 (2004) 25
F. AMYOT, V. BOUDY, K. JURSKI and J. COUNORD, ITBM-RBM 23 (2002) 285
C. CHRETIEN, V. BOUDY, P. ALLAIN and J. C. CHAUMEIL, J Control Release 96 (2004) 369
M. VARELA, M. I. REAL, M. BURREL, et al., J. Hepatol. 47 (2007) 159
J. M. LLOVET, M. I. REAL, X. MONTAÑA, et al., Lancet 359 (2002) 1734
P. JOHNSON, C. KALAYCI and N. DOBBS, J. Hepatol. 13(1) (1991) 120
J. RICHARDS, in “The Role of Polymer Permeability in the Control of Drug Release. Polymer Permeability” (London, Elsevier Applied Science Publisher, 1985) Chapt. 6, p. 217
T. HIGUCHI, J. Pharm. Sci. 52(12) (1963) 1145
Z. LIU, R. CHEUNG, X. Y. WU, J. R. BALLINGER, et al., J. Control Release 77 (2001) 213
A. SAWAYA, R. FICKAT, J. P. BENOIT, et al., J. Microencapsul. 5 (1988) 23
C. L. SCHAUF, M. MOFFETT and S. B. MOFFETT, in “Human Physiology. Foundations and Frontiers” (Edward. F. Murphy, 1990)
X. Y. WU, G. ESHUN and Y. ZHOU, J. Pharm. Sci. 87 (1998) 255
D. REICHENBERG, J. Am. Chem. Soc. 75 (1953) 589
M. ABDEKHODAIE and X. Y. WU, Biomaterials 27 (2006) 3652
G. BOYD, A. ADAMSON and L. MYERS J. Am. Chem. Soc. 69 (1947) 2836
F. AMYOT, K. JURSKI, G. DUFAUX and G. GUIFFANT, Int. Comm. Heat Mass Transfer 20(9) (2002) 623
X. LI, D.J. HIRSH, D. CABRAL-LILLY, A. ZIRKEL, et al., Biochim. Biophys. Acta 1415 (1998) 23
GUIDANCE FOR INDUSTRY: extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlations, Food and Drug Administration, (1997)
G. SCHELIECKER, C. SCHMIDT, S. FUSCHS, et al., J. Control Release 94 (2004) 25
N. CHIDAMBARAM and D. J. BURGESS, AAPS Pharm. Sci. 1(3) (1999) article 11
G. MINOTTI, P. MENNA and E. SALVATORELLI, Pharmacol. Rev. 56(2) (2004) 185
K. HONG, A. KHWAJA, E. LIAPI, et al., Clin. Cancer Res. 12(8) (2006) 2563
Acknowledgements
VG would like to thank Biocompatibles UK Ltd for funding her PhD. The authors would like to thank Dr. Ronnie Poon, from Queen Mary’s Hospital, Hong Kong, for provision of the PK data from PRECISION clinical trial.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gonzalez, M.V., Tang, Y., Phillips, G.J. et al. Doxorubicin eluting beads—2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci: Mater Med 19, 767–775 (2008). https://doi.org/10.1007/s10856-006-0040-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10856-006-0040-y